TY - JOUR
T1 - Early intervention of the perioperative multidisciplinary team approach decreases the adverse events during neoadjuvant chemotherapy for esophageal cancer patients
AU - Shirakawa, Yasuhiro
AU - Noma, Kazuhiro
AU - Maeda, Naoaki
AU - Tanabe, Shunsuke
AU - Sakurama, Kazufumi
AU - Sonoyama-Hanaoka, Ayumi
AU - Yoshitomi, Aiko
AU - Kohno-Yamanaka, Reiko
AU - Soga, Yoshihiko
AU - Fujiwara, Toshiyoshi
N1 - Funding Information:
The authors would like to acknowledge all team members of PERiO. The authors also would like to thank FORTE (https://www.forte-science.co.jp/ ) for the English language review.
Publisher Copyright:
© 2021, The Japan Esophageal Society.
PY - 2021/10
Y1 - 2021/10
N2 - Background: Multidisciplinary team (MDT) approach has become a standard for perioperative patient care, including in esophageal cancer. In our institution, the Perioperative Management Center (PERiO) has been doing an MDT approach for patients undergoing esophageal cancer surgery since 2009. On the other hand, neoadjuvant therapy has also been becoming standard for many malignancies, including esophageal cancer. In Japan, neoadjuvant chemotherapy (NAC) for esophageal cancer is standard now. However, there have been no reports about when is the best time to start the MDT approach for patients with neoadjuvant therapy. In this study, the best start time for the MDT approach for esophageal cancer patients with NAC was examined from the perspective of adverse events during chemotherapy and perioperative period. Methods: All cases underwent thoracoscopic esophagectomy in the prone position (TEPP) after NAC. The PERiO Intervention group that started before NAC (n = 100) was compared with the PERiO Intervention group that started after NAC (n = 77). Eventually, 54 paired cases were matched by propensity score matching. Results: The adverse event rate during chemotherapy, especially oral complications, was significantly decreased in the PERiO Intervention started before the NAC group (P = 0.007). Furthermore, weight loss during the period from chemotherapy to surgery was significantly reduced in the group that started before NAC (P = 0.033). Conclusion: The MDT approach should be started before NAC in patients undergoing esophageal cancer surgery to prevent adverse events during chemotherapy and provide safe perioperative conditions.
AB - Background: Multidisciplinary team (MDT) approach has become a standard for perioperative patient care, including in esophageal cancer. In our institution, the Perioperative Management Center (PERiO) has been doing an MDT approach for patients undergoing esophageal cancer surgery since 2009. On the other hand, neoadjuvant therapy has also been becoming standard for many malignancies, including esophageal cancer. In Japan, neoadjuvant chemotherapy (NAC) for esophageal cancer is standard now. However, there have been no reports about when is the best time to start the MDT approach for patients with neoadjuvant therapy. In this study, the best start time for the MDT approach for esophageal cancer patients with NAC was examined from the perspective of adverse events during chemotherapy and perioperative period. Methods: All cases underwent thoracoscopic esophagectomy in the prone position (TEPP) after NAC. The PERiO Intervention group that started before NAC (n = 100) was compared with the PERiO Intervention group that started after NAC (n = 77). Eventually, 54 paired cases were matched by propensity score matching. Results: The adverse event rate during chemotherapy, especially oral complications, was significantly decreased in the PERiO Intervention started before the NAC group (P = 0.007). Furthermore, weight loss during the period from chemotherapy to surgery was significantly reduced in the group that started before NAC (P = 0.033). Conclusion: The MDT approach should be started before NAC in patients undergoing esophageal cancer surgery to prevent adverse events during chemotherapy and provide safe perioperative conditions.
KW - Esophageal cancer
KW - Multidisciplinary team approach
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85106321679&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106321679&partnerID=8YFLogxK
U2 - 10.1007/s10388-021-00844-y
DO - 10.1007/s10388-021-00844-y
M3 - Article
C2 - 33999305
AN - SCOPUS:85106321679
SN - 1612-9059
VL - 18
SP - 797
EP - 805
JO - Esophagus
JF - Esophagus
IS - 4
ER -